AFMD News and Press, Affimed N.V. From 03/23/23

AFM13 combination with AB-101 NK cells: On track for IND filing in H1 2023 and initiation of clinical study in 2023 AFM13 monotherapy REDIRECT data: Oral presentation at the AACR annual meeting AFM24: Data from the three ongoing studies expected to be presented at scientific conferences i...

2023-03-22 12:28:19 ET Affimed ( NASDAQ: AFMD ) is scheduled to announce FY earnings results on Thursday, March 23rd, before market open. The consensus EPS Estimate is -$0.59 and the consensus Revenue Estimate is $39.92M. Over the last 3 months, EPS estimates have se...

HEIDELBERG, Germany, March 16, 2023 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that it will release full year 2022 results and corporate update on Thursday, March...

2023-03-09 05:55:25 ET Affimed's ( NASDAQ: AFMD ) unit AbCheck said it has completed the technology development activities under a 2019 research grant agreement with the Ministry of Industry and Trade of the Czech Republic. AbCheck, which is focused on antibody d...

PLZEN, Czech Republic, March 09, 2023 (GLOBE NEWSWIRE) -- AbCheck s.r.o., a technology company delivering disruptive antibody discovery and development solutions for challenging targets, announced today that it has successfully completed the technology development activities specified under the t...

HEIDELBERG, Germany, Feb. 22, 2023 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today its Chief Executive Officer, Dr. Adi Hoess, will participate in a fireside chat...

Affimed's ( NASDAQ: AFMD ) unit AbCheck said it is collaborating with a biotech company which develops antibodies targeting peripheral neural response, funded by an European venture capital firm. Under the agreement, AbCheck will use its technology suite consisting of antibody discove...

PLZEN, Czech Republic, Feb. 21, 2023 (GLOBE NEWSWIRE) -- AbCheck s.r.o., a technology company delivering disruptive antibody discovery and development solutions for challenging targets, announced today that it has entered into a collaboration with a biotech company developing antibodies targeting...

Summary Affimed has decided to focus on testing AFM13 in combination with Artiva's AB-101 NK cell product for the treatment of peripheral T-cell lymphoma after underwhelming monotherapy data. Peripheral T-cell lymphomas are highly aggressive and difficult-to-treat forms of lymphoma with...

HEIDELBERG, Germany, Feb. 08, 2023 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today its Chief Executive Officer, Dr. Adi Hoess, will present at the SVB Securities ...